Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen + Durvalumab in Advanced Solid Tumors
NCT03421353Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danvatirsen in solid tumor (advanced stage) (7 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Tolerated Dose at 6 months, Area Under the Plasma Concentration-Time Curve at Steady State at 9 weeks and 1 more. Started Feb 2018; status: completed.
02
Drugs
danvatirsen
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03421353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421353.